Patient Types/Special Populations: Treatment Naïve

DTG: Metabolic Data Update

DTG: Metabolic Data Update

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG: Metabolic Data Update

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X
STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Dolutegravir Based Regimens

STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Dolutegravir Based Regimens

X
DTG/3TC: Real-World Evidence

DTG/3TC: Real-World Evidence

An Update from CROI 2020

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

DTG/3TC: Real-World Evidence

An Update from CROI 2020

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X
M184V and the GEMINI Studies

M184V and the GEMINI Studies

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Dolutegravir Based Regimens

M184V and the GEMINI Studies

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Dolutegravir Based Regimens

X
Dovato for Treatment Naïve Patients: GEMINI-1 & GEMINI-2

Dovato for Treatment Naïve Patients: GEMINI-1 & GEMINI-2

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

Dovato for Treatment Naïve Patients: GEMINI-1 & GEMINI-2

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X
The Use of Tivicay plus Epivir for Treatment-Naiive Adults with HIV-1

The Use of Tivicay plus Epivir for Treatment-Naiive Adults with HIV-1

GEMINI-1 and GEMINI-2 Studies

Michael Aboud, VP, Global Medical Lead, Dolutegravir

The Use of Tivicay plus Epivir for Treatment-Naiive Adults with HIV-1

GEMINI-1 and GEMINI-2 Studies

Michael Aboud, VP, Global Medical Lead, Dolutegravir

X
DTG+3TC: GEMINI 144-Week Data

DTG+3TC: GEMINI 144-Week Data

An Update from HIV GLASGOW 2020

Nneka Nwokolo, Senior Global Medical Director

Dolutegravir Based Regimens

DTG+3TC: GEMINI 144-Week Data

An Update from HIV GLASGOW 2020

Nneka Nwokolo, Senior Global Medical Director

Dolutegravir Based Regimens

X
DTG/3TC: Confirmed Virologic Withdrawals in the GEMINI-1 and -2 Studies

DTG/3TC: Confirmed Virologic Withdrawals in the GEMINI-1 and -2 Studies

Nneka Nwokolo, Senior Global Medical Director

Dolutegravir Based Regimens

DTG/3TC: Confirmed Virologic Withdrawals in the GEMINI-1 and -2 Studies

Nneka Nwokolo, Senior Global Medical Director

Dolutegravir Based Regimens

X
DTG/3TC: Barrier to Resistance

DTG/3TC: Barrier to Resistance

Jan van Lunzen, Head of Translational Medical Research

Dolutegravir Based Regimens

DTG/3TC: Barrier to Resistance

Jan van Lunzen, Head of Translational Medical Research

Dolutegravir Based Regimens

X
Antiretroviral Therapy and Weight Gain

Antiretroviral Therapy and Weight Gain

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

Antiretroviral Therapy and Weight Gain

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X
GEMINI 144 Week: Efficacy and Safety

GEMINI 144 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

GEMINI 144 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X
GEMINI 48 Week: Adherence Analysis

GEMINI 48 Week: Adherence Analysis

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

GEMINI 48 Week: Adherence Analysis

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X
STAT 24 Week: Feasibility, Efficacy and Safety

STAT 24 Week: Feasibility, Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

STAT 24 Week: Feasibility, Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Connect with our Medical Experts

Find my ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Talk to a Medical Expert

Connect now with a live ViiV Medical Expert.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1-888-226-8434

Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-332-1088 or www.fda.gov/medwatch